Critical Demand

To understand the level of critical demand there is for new drug therapies; one can look at the market opportunities for hemp-based solutions. The listed ailments are running rampant in our ever-evolving world and affecting millions of people’s ways of life. Sadly, the demand for new options grows every day, and OmniCanna has much to offer the people of the world who are suffering.

AIDS/HIV $12.6 US$ 12.6 Billion in 2010. TechNavio's analysts forecast the Global HIV Drugs market to reach $15.5 billion by 2014.

Alzheimer’s $8.3 The global Alzheimer's disease treatment market was valued at $8.3 billion in 2010 $9.0 billion by 2016.

Anti-Aging $50.0 Currently topping out around $50 billion a year. Global Anti-Aging Products Market to Reach $291.9 Billion by 2015.

Asthma $25.0 Overall sales in the asthma and COPD drugs market were worth $25 billion in 2008, and increased to an estimated $26 billion in 2009. By 2014, it is projected to increase to $31 billion, for a 5-year compound annual growth rate (CAGR) of 3.3%.

Arthritis $35.0 The global market for arthritis drugs was worth $35 billion in 2008.

Autism $22.0 Antipsychotics are among the biggest selling and most profitable of all drugs, generating $22 billion in global sales in 2008.

Cancer $75.0 Global sales of cancer drugs will grow at a compounded annual rate of 12 to 15 percent, reaching $75 to $80 billion by 2012.

Chronic Pain Management $22.0 The global pain market recorded sales of $22.0 billion in 2010, rising at a compound annual growth rate (CAGR) of 8.9%market value is set to contract to $18.7 billion by 2016.

Diabetes $25.0 In 2009, the diabetes treatment market generated worldwide sales of over $25 billion.

Digestive Diseases $6.0 The global market for medical enzymes is estimated at $6 billion in 2010. The market is growing at a compounded annual growth rate (CAGR) of 3.9%, to reach $7.2 billion in 2015. Therapeutic enzymes are the biggest segment in terms of revenues generated. This sector was valued at $5.3 billion in 2010 and is expected to increase at a 3.6% compound Enzymes used in molecular research will experience the fastest compound annual growth rate (CAGR), 6.2%, over the study period. This sector was worth $546 million in 2010 and should reach nearly $739 million by 2015. Annual growth rate (CAGR) to reach $6.3 billion in 2015.

Glaucoma $14.0 Over $14 billion in 2009 The global glaucoma pharmaceuticals market is projected to exceed $3.35 billion by 2015.

High Blood Pressure $25.0 The Prescription drug market for the treatment of Hypertension is to continue to rise in value from the $25 billion market.

Influenza $28.0 In 2009, the global market for antiviral drugs attained total sales of over $28 billion.

Multiple Sclerosis $8.0 The multiple sclerosis (MS) treatments market is one of the largest for CNS disorders, with total pharmaceutical revenues of over $8 billion in 2009. Revenues for MS treatments will rise significantly from 2010 to 2025.

PTSD $72.0 $72 billion from top ten drug sales.

* Figures shown above are for illustration purposes only.